High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women

Pamela A Magistrado; Daniel Minja; Justin Doritchamou; Nicaise Tuikue Ndam; Davis John; Christentze Schmiegelow; Achille Massougbodji; Madeleine Dahlbäck; Sisse B Ditlev; Vera V Pinto; Mafalda Resende; John Lusingu; Thor G Theander; Ali Salanti; Morten A Nielsen

doi:10.1016/j.vaccine.2010.10.080

High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women

Pamela A Magistrado, Daniel Minja, Justin Doritchamou, Nicaise Tuikue Ndam, Davis John, Christentze Schmiegelow, Achille Massougbodji, Madeleine Dahlbäck, Sisse B Ditlev, Vera V Pinto, Mafalda Resende, John Lusingu, Thor G Theander, Ali Salanti, Morten A Nielsen

37 Citations (Scopus)

Abstract

Malaria during pregnancy is a major cause of intra-uterine growth-retardation and infant death in sub-Saharan Africa. Ideally, this could be prevented by a vaccine delivered before the first pregnancy. Antibodies against domain DBL4e{open} from VAR2CSA has been shown to inhibit adhesion of laboratory isolates to the placental receptor chondroitin sulfate A. In this study, the binding inhibitory efficacy of IgG elicited by two different DBL4e{open} recombinant proteins was tested on a panel of fresh clinical isolates from pregnant women living in Benin and Tanzania. The most promising recombinant protein elicited antibodies with similar efficacy as pooled plasma from immune multi-gravid African women.

Original language	English
Journal	Vaccine
Volume	29
Issue number	3
Pages (from-to)	437-43
Number of pages	7
ISSN	0264-410X
DOIs	https://doi.org/10.1016/j.vaccine.2010.10.080
Publication status	Published - 10 Jan 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2010.10.080

Cite this

Magistrado, P. A., Minja, D., Doritchamou, J., Ndam, N. T., John, D., Schmiegelow, C., Massougbodji, A., Dahlbäck, M., Ditlev, S. B., Pinto, V. V., Resende, M., Lusingu, J., Theander, T. G., Salanti, A., & Nielsen, M. A. (2011). High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine, 29(3), 437-43. https://doi.org/10.1016/j.vaccine.2010.10.080

Magistrado, PA, Minja, D, Doritchamou, J, Ndam, NT, John, D, Schmiegelow, C, Massougbodji, A, Dahlbäck, M, Ditlev, SB, Pinto, VV, Resende, M, Lusingu, J, Theander, TG , Salanti, A & Nielsen, MA 2011, 'High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women', Vaccine, vol. 29, no. 3, pp. 437-43. https://doi.org/10.1016/j.vaccine.2010.10.080

@article{c078cbee630a46c888cd09b7ab8f4aec,

title = "High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women",

abstract = "Malaria during pregnancy is a major cause of intra-uterine growth-retardation and infant death in sub-Saharan Africa. Ideally, this could be prevented by a vaccine delivered before the first pregnancy. Antibodies against domain DBL4e{open} from VAR2CSA has been shown to inhibit adhesion of laboratory isolates to the placental receptor chondroitin sulfate A. In this study, the binding inhibitory efficacy of IgG elicited by two different DBL4e{open} recombinant proteins was tested on a panel of fresh clinical isolates from pregnant women living in Benin and Tanzania. The most promising recombinant protein elicited antibodies with similar efficacy as pooled plasma from immune multi-gravid African women.",

author = "Magistrado, {Pamela A} and Daniel Minja and Justin Doritchamou and Ndam, {Nicaise Tuikue} and Davis John and Christentze Schmiegelow and Achille Massougbodji and Madeleine Dahlb{\"a}ck and Ditlev, {Sisse B} and Pinto, {Vera V} and Mafalda Resende and John Lusingu and Theander, {Thor G} and Ali Salanti and Nielsen, {Morten A}",

year = "2011",

month = jan,

day = "10",

doi = "10.1016/j.vaccine.2010.10.080",

language = "English",

volume = "29",

pages = "437--43",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women

AU - Magistrado, Pamela A

AU - Minja, Daniel

AU - Doritchamou, Justin

AU - Ndam, Nicaise Tuikue

AU - John, Davis

AU - Schmiegelow, Christentze

AU - Massougbodji, Achille

AU - Dahlbäck, Madeleine

AU - Ditlev, Sisse B

AU - Pinto, Vera V

AU - Resende, Mafalda

AU - Lusingu, John

AU - Theander, Thor G

AU - Salanti, Ali

AU - Nielsen, Morten A

PY - 2011/1/10

Y1 - 2011/1/10

N2 - Malaria during pregnancy is a major cause of intra-uterine growth-retardation and infant death in sub-Saharan Africa. Ideally, this could be prevented by a vaccine delivered before the first pregnancy. Antibodies against domain DBL4e{open} from VAR2CSA has been shown to inhibit adhesion of laboratory isolates to the placental receptor chondroitin sulfate A. In this study, the binding inhibitory efficacy of IgG elicited by two different DBL4e{open} recombinant proteins was tested on a panel of fresh clinical isolates from pregnant women living in Benin and Tanzania. The most promising recombinant protein elicited antibodies with similar efficacy as pooled plasma from immune multi-gravid African women.

AB - Malaria during pregnancy is a major cause of intra-uterine growth-retardation and infant death in sub-Saharan Africa. Ideally, this could be prevented by a vaccine delivered before the first pregnancy. Antibodies against domain DBL4e{open} from VAR2CSA has been shown to inhibit adhesion of laboratory isolates to the placental receptor chondroitin sulfate A. In this study, the binding inhibitory efficacy of IgG elicited by two different DBL4e{open} recombinant proteins was tested on a panel of fresh clinical isolates from pregnant women living in Benin and Tanzania. The most promising recombinant protein elicited antibodies with similar efficacy as pooled plasma from immune multi-gravid African women.

U2 - 10.1016/j.vaccine.2010.10.080

DO - 10.1016/j.vaccine.2010.10.080

M3 - Journal article

C2 - 21075162

SN - 0264-410X

VL - 29

SP - 437

EP - 443

JO - Vaccine

JF - Vaccine

IS - 3

ER -

High efficacy of anti DBL4e-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this